Trial Profile
A Phase I, Randomized, Double-Blind, Placebo-Controlled, SAD and MAD Intravenous Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ARGX-113 in Healthy Males and Female Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Efgartigimod alfa (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy; Idiopathic thrombocytopenic purpura; Myasthenia gravis; Pemphigus vulgaris
- Focus Adverse reactions; First in man
- Sponsors argenx
- 24 Jul 2018 Results presented in an argenx Media Release.
- 24 Jul 2018 According to an argenx media release, full study results were published in the Journal of Clinical Investigation (JCI).
- 01 Mar 2018 Status changed from recruiting to completed.